What is ALEC's market cap?

Alector, Inc. (ALEC) is a listed stock with a live quote. The latest market cap on this page is $242M.

Where is Alector, Inc. headquartered?

Alector, Inc. is headquartered in South San Francisco, CA.

How do I get ALEC news from the API?

Call GET /v1/news?tickers=ALEC. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does ALEC news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ALEC, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the ALEC price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email sales@marketnewsapi.com.

ALEC · NASDAQ

Alector, Inc.

$2.17 -0.12 (-5.24%)

Company overview

Alector, Inc. is a clinical-stage biopharmaceutical company that develops therapies for the treatment of neurodegenerative diseases. Its product candidates include AL001, a humanized recombinant monoclonal antibody in Phase III clinical trials for frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, and AL101, which is in Phase I clinical trials for neurodegenerative diseases, including Alzheimer's and Parkinson's. The company also offers AL002, a product candidate in Phase II clinical trials for Alzheimer's disease, and AL003, which is in Phase I clinical trials for Alzheimer's disease. Its pipeline includes AL044, which targets MS4A4A, a risk gene for Alzheimer's disease.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $242M
Employees: 175
Headquarters: South San Francisco, CA
Website: alector.com
CEO: Arnon Rosenthal
Listed: February 7, 2019
P/E: -1.78
Dividend yield: 0.00%

Company financials

Revenue: $18.4M
Gross profit: $16.3M
Operating income: -$137M
EBITDA: -$125M
Net income: -$125M
EPS: -$1.19
Total assets: $240M
Total debt: $34.5M
Gross margin: 88.68%
Net margin: -680.83%
Earnings yield: -56.13%

Revenue segmentation

By product (FY 2021)

By region (FY 2021)

No geographic segmentation.

Showing FY 2021

Price chart

ALEC 1D NASDAQ O2.14H2.30L2.08C2.28+0.23 (+11.22%)Vol1.48M

News

Ticker	Type	Headline	Source	Published
ALECAlector, Inc.	Stock news	BRIEF-Alector Q3 Basic EPS USD 1.11	Reuters	Nov 5, 4:18:40 PM ET
ALECAlector, Inc.	Press release	Alector Reports Third Quarter 2026 Financial Results and Provides Business Update	GlobeNewswire	Nov 5, 4:05:29 PM ET
ALECAlector, Inc.	Stock news	Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know	Zacks Investment Research	Oct 29, 11:06:57 AM ET
ALECAlector, Inc.	Press release	Alector Announces Pricing of Underwritten Offering	GlobeNewswire	Oct 16, 7:30:00 AM ET
ALECAlector, Inc.	Stock news	Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday	Benzinga	Oct 15, 8:31:09 AM ET
ALECAlector, Inc.	Stock news	Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript	Seeking Alpha	Oct 13, 6:52:46 PM ET
ALECAlector, Inc.	Stock news	Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies	MarketBeat	Oct 13, 3:02:47 PM ET
ALECAlector, Inc.	Press release	Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline	GlobeNewswire	Oct 7, 4:05:00 PM ET
ALECAlector, Inc.	Press release	Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases	GlobeNewswire	Oct 5, 7:00:00 AM ET
ALECAlector, Inc.	Stock news	Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript	Seeking Alpha	Sep 15, 1:11:40 PM ET
ALECAlector, Inc.	Stock news	Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript	Seeking Alpha	Sep 15, 7:31:39 AM ET
ALECAlector, Inc.	Stock news	Comparing Alector (NASDAQ:ALEC) and Sarepta Therapeutics (NASDAQ:SRPT)	Defense World	Sep 8, 3:59:14 AM ET
ALECAlector, Inc.	Press release	Alector to Participate in Upcoming Healthcare Conferences	GlobeNewswire	Sep 3, 4:05:00 PM ET
ALECAlector, Inc.	Stock news	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates	Zacks Investment Research	Aug 6, 8:12:29 PM ET
ALECAlector, Inc.	Stock news	Alector and GSK partnership to end after dementia, Alzheimer's drug failures	Reuters	Jul 8, 5:20:31 PM ET
ALECAlector, Inc.	Stock news	Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates	Zacks Investment Research	May 7, 8:12:11 PM ET
ALECAlector, Inc.	Press release	Alector Reports First Quarter 2026 Financial Results and Provides Business Update	GlobeNewswire	May 7, 4:05:00 PM ET
ALECAlector, Inc.	Stock news	Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know	Zacks Investment Research	May 7, 11:00:51 AM ET
ALECAlector, Inc.	Press release	Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis	GlobeNewswire	Apr 29, 4:05:00 PM ET
ALECAlector, Inc.	Stock news	Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross	Zacks Investment Research	Mar 10, 10:55:47 AM ET

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.